Insider Trading

Notable insider buying and selling activity across public companies.

Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.

Articles

11,898 total articles

Nuveen Churchill Direct Lending VP John McCally Buys $99,525 Stock

Nuveen Churchill Direct Lending VP John McCally Buys $99,525 Stock

Nuveen Churchill Direct Lending Corp. Vice President and Secretary John McCally executed a direct purchase of company stock, acquiring 7,500 shares on May 15, 2026. The transaction occurred at a price of $13.27 per share, representing a significant premium over the stock's prevailing market value and highlighting internal confidence despite recent …

Block Insider Sale: Director Anthony Eisen Offloads $1.32M in Class A Shares Under Pre-Arranged Plan

Block Insider Sale: Director Anthony Eisen Offloads $1.32M in Class A Shares Under Pre-Arranged Plan

Block, Inc. director Anthony Mathew Eisen executed a series of share sales totaling $1,323,480 this week, disposing of 18,000 Class A Common Stock units between June 22 and 24, 2026. The transactions, conducted at prices ranging from $72.29 to $74.28 per share, were facilitated through a Rule 10b5-1 trading plan established on March 2, 2026. Follow…

AMREP Executives Increase Holdings Amid Operational Improvements

AMREP Executives Increase Holdings Amid Operational Improvements

James H. Dahl and Rainey E. Lancaster, identified as ten percent owners of AMREP CORP. (NASDAQ:AXR), have collectively acquired 3,075 common shares on June 22, 2026, totaling $78,666. The purchase, executed at a weighted average price of $25.5827 per share, reflects confidence in the company's valuation, which currently sits near its Fair Value wit…

Heritage Insurance Holdings Executive Sharon Binnun Executes $224K Stock Sale Under Pre-Arranged Plan

Heritage Insurance Holdings Executive Sharon Binnun Executes $224K Stock Sale Under Pre-Arranged Plan

Sharon Binnun, Chief Accounting Officer at Heritage Insurance Holdings, Inc. (NASDAQ:HRTG), executed a sale of 9,200 shares of the company's common stock on June 22, 2026. The transaction, valued at approximately $224,102, was conducted through a Rule 10b5-1 trading plan established on December 12, 2025. The sale price per share ranged from $24.00 …

AmpliTech Group Director Sells Shares Amid Recent Stock Volatility

AmpliTech Group Director Sells Shares Amid Recent Stock Volatility

AmpliTech Group, Inc. (NASDAQ: AMPG) director Daniel Richard Mazziota executed a sale of 10,000 shares of the company’s common stock on June 23, 2026. The transaction was valued at $77,146, with each share sold at a price of $7.7146. Following the sale, Mazziota’s direct holdings in AmpliTech Group, Inc. common stock stand at 237,743 shares. The sa…

Quantumscape CFO Executes Stock Sale Under Pre-Arranged Trading Plan

Quantumscape CFO Executes Stock Sale Under Pre-Arranged Trading Plan

Kevin Hettrich, Chief Financial Officer of QuantumScape Corp (NYSE: QS), executed a sale of 9,800 shares of the company’s Class A Common Stock on June 22, 2026, totaling $77,811 under a Rule 10b5-1 trading plan adopted on June 11, 2025. The weighted average sale price was $7.9399 per share, with individual prices ranging from $7.585 to $8.435. Foll…

Verastem CEO Executes Stock Sale Amid Clinical Trial Momentum

Verastem CEO Executes Stock Sale Amid Clinical Trial Momentum

Verastem, Inc. (NASDAQ: VSTM) President and CEO Dan Paterson completed a transaction involving the sale of 20,871 common shares on June 22, 2026. Executed at $4.18 per share, the transaction yielded $87,240. This sale was necessitated by statutory withholding requirements tied to the vesting of restricted stock units rather than a discretionary dec…

Verastem Executive Sale and Clinical Trial Updates

Verastem Executive Sale and Clinical Trial Updates

Verastem, Inc. (NASDAQ:VSTM) reported a recent stock sale by its Chief Financial Officer, Daniel Calkins, alongside positive updates from its clinical development pipeline. While Calkins disposed of 4,089 shares to cover withholding obligations tied to restricted stock unit vesting, the company continues to advance its oncology programs. The stock …